US4474893A
(en)
|
1981-07-01 |
1984-10-02 |
The University of Texas System Cancer Center |
Recombinant monoclonal antibodies
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US4801687A
(en)
|
1986-10-27 |
1989-01-31 |
Bioprobe International, Inc. |
Monoclonal antibody purification process using protein A
|
FI884924A
(fi)
|
1987-10-28 |
1989-04-29 |
Oncogen |
Humanimmuglobulin som producerats med hybrid-dna-teknik.
|
US5476996A
(en)
|
1988-06-14 |
1995-12-19 |
Lidak Pharmaceuticals |
Human immune system in non-human animal
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5151504A
(en)
|
1989-11-17 |
1992-09-29 |
E. R. Squibb & Sons, Inc. |
Method for purification of monoclonal antibodies
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
WO1991010741A1
(en)
|
1990-01-12 |
1991-07-25 |
Cell Genesys, Inc. |
Generation of xenogeneic antibodies
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
ES2108048T3
(es)
|
1990-08-29 |
1997-12-16 |
Genpharm Int |
Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
GB9022543D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
EP0523949B1
(en)
|
1991-07-15 |
2003-06-25 |
The Wellcome Foundation Limited |
Production of antibodies
|
ES2227512T3
(es)
|
1991-12-02 |
2005-04-01 |
Medical Research Council |
Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
|
SE9400088D0
(sv)
|
1994-01-14 |
1994-01-14 |
Kabi Pharmacia Ab |
Bacterial receptor structures
|
DE19742706B4
(de)
|
1997-09-26 |
2013-07-25 |
Pieris Proteolab Ag |
Lipocalinmuteine
|
US6818418B1
(en)
|
1998-12-10 |
2004-11-16 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
ATE447617T1
(de)
|
1999-04-15 |
2009-11-15 |
Crucell Holland Bv |
Verwendung von rekombinanten proteinen in menschlichen zellen
|
SE9901379D0
(sv)
|
1999-04-19 |
1999-04-19 |
Pharmacia & Upjohn Ab |
Receptor structures
|
DE19932688B4
(de)
|
1999-07-13 |
2009-10-08 |
Scil Proteins Gmbh |
Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
|
ATE378403T1
(de)
|
2000-11-30 |
2007-11-15 |
Medarex Inc |
Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
|
WO2003011911A1
(en)
|
2001-07-31 |
2003-02-13 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to pd-1
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
ES2729974T3
(es)
|
2003-01-23 |
2019-11-07 |
Ono Pharmaceutical Co |
Anticuerpo específico de PD-1 y CD3 humanas
|
DE10324447A1
(de)
|
2003-05-28 |
2004-12-30 |
Scil Proteins Gmbh |
Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
|
CA2970873C
(en)
|
2005-05-09 |
2022-05-17 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
EP3222634A1
(en)
|
2007-06-18 |
2017-09-27 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor pd-1
|
CA2736829C
(en)
|
2008-09-12 |
2018-02-27 |
Isis Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
US9181342B2
(en)
|
2008-09-12 |
2015-11-10 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
AU2009296392B2
(en)
|
2008-09-26 |
2016-06-02 |
Dana-Farber Cancer Institute, Inc. |
Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
|
CA2772162C
(en)
|
2009-08-27 |
2018-05-22 |
Covagen Ag |
Anti-il-17a fynomers and medical uses thereof
|
IL300733A
(en)
*
|
2010-03-05 |
2023-04-01 |
Univ Johns Hopkins |
Compositions and methods for antibodies and fusion proteins targeting immune modulation
|
CA2791930A1
(en)
|
2010-03-11 |
2011-09-15 |
Kerry Louise Tyson |
Pd-1 antibody
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
ES2893855T3
(es)
*
|
2011-08-11 |
2022-02-10 |
Ono Pharmaceutical Co |
Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1
|
NZ630551A
(en)
|
2012-04-20 |
2017-11-24 |
Merus Nv |
Methods and means for the production of ig-like molecules
|
NZ630563A
(en)
|
2012-09-27 |
2017-04-28 |
Merus Nv |
Bispecific igg antibodies as t cell engagers
|
WO2014161509A1
(en)
|
2013-04-05 |
2014-10-09 |
The University Of Hong Kong |
Novel pd1 isoforms, and uses thereof for potentiating immune responses
|
EP2992017B1
(en)
|
2013-05-02 |
2020-11-18 |
AnaptysBio, Inc. |
Antibodies directed against programmed death-1 (pd-1)
|
JP6563906B2
(ja)
|
2013-05-31 |
2019-08-21 |
ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. |
Pd−1に結合する抗原結合蛋白質
|
WO2014209804A1
(en)
*
|
2013-06-24 |
2014-12-31 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
US10077305B2
(en)
|
2013-09-10 |
2018-09-18 |
Medimmune Limited |
Antibodies against PD-1 and uses thereof
|
AU2013400609B9
(en)
|
2013-09-13 |
2020-03-05 |
Beigene Switzerland Gmbh |
Anti-PD1 antibodies and their use as therapeutics and diagnostics
|
CR20160319A
(es)
|
2013-12-12 |
2016-11-08 |
Jiangsu Hengrui Medicine Co |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
WO2015125652A1
(ja)
*
|
2014-02-21 |
2015-08-27 |
Idacセラノスティクス株式会社 |
固形がんの治療剤
|
EP3156072B1
(en)
*
|
2014-06-11 |
2020-08-19 |
IDAC Theranostics, Inc. |
Method for reducing side effects of immune checkpoint control agent
|
NZ728688A
(en)
|
2014-07-22 |
2023-06-30 |
Cb Therapeutics Inc |
Anti-pd-1 antibodies
|
CN105330740B
(zh)
|
2014-07-30 |
2018-08-17 |
珠海市丽珠单抗生物技术有限公司 |
抗pd-1抗体及其应用
|
GB201419084D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-PD-1 antibodies
|
EP3218409A2
(en)
|
2014-11-11 |
2017-09-20 |
Sutro Biopharma, Inc. |
Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
EP3916017A1
(en)
|
2014-12-22 |
2021-12-01 |
PD-1 Acquisition Group, LLC |
Anti-pd-1 antibodies
|
EA201791768A1
(ru)
|
2015-02-06 |
2018-07-31 |
КАДМОН КОРПОРЕЙШН, ЭлЭлСи |
Иммуномодулирующие агенты
|
CN105061597B
(zh)
|
2015-06-09 |
2016-04-27 |
北京东方百泰生物科技有限公司 |
一种抗pd-1的单克隆抗体及其获得方法
|
KR20180019725A
(ko)
|
2015-06-23 |
2018-02-26 |
메모리얼 슬로안-케터링 캔서 센터 |
신규의 피디 1 면역 조절제
|
EP3322732A2
(en)
|
2015-07-13 |
2018-05-23 |
Cytomx Therapeutics Inc. |
Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
|
CN106699888B
(zh)
|
2015-07-28 |
2020-11-06 |
上海昀怡健康科技发展有限公司 |
一种pd-1抗体及其制备方法和应用
|
CN114272371A
(zh)
|
2015-07-29 |
2022-04-05 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
PT3328419T
(pt)
|
2015-07-30 |
2021-11-26 |
Macrogenics Inc |
Moléculas de ligação pd-1 e métodos de utilização
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
SG10201914109VA
(en)
|
2015-08-11 |
2020-02-27 |
Wuxi Biologics Cayman Inc |
Novel anti-pd-1 antibodies
|
WO2017024515A1
(en)
|
2015-08-11 |
2017-02-16 |
Wuxi Biologics (Cayman) Inc. |
Novel anti-pd-1 antibodies
|
MA48579A
(fr)
|
2015-09-01 |
2020-03-18 |
Agenus Inc |
Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
|
CA3000638C
(en)
|
2015-09-29 |
2024-02-27 |
Asia Biotech Pte. Ltd. |
Pd-1 antibodies and uses thereof
|
EA201890790A1
(ru)
|
2015-09-29 |
2018-10-31 |
Селджин Корпорейшн |
Связывающие pd-1 белки и способы их применения
|
RS62450B1
(sr)
|
2015-10-02 |
2021-11-30 |
Hoffmann La Roche |
Anti-pd1 antitela i postupci primene
|
SI3368572T1
(sl)
|
2015-10-02 |
2022-10-28 |
Symphogen A/S |
Protitelesa proti PD-1 in sestavki
|
BR112018008891A8
(pt)
|
2015-11-03 |
2019-02-26 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
|
CN106699889A
(zh)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技(上海)有限公司 |
抗pd-1抗体及其治疗用途
|
KR20180085793A
(ko)
|
2015-12-02 |
2018-07-27 |
주식회사 에스티큐브 |
글리코실화된 pd-1에 대해 특이적인 항체 및 이의 사용 방법
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Pd−1に対する抗体分子およびその使用
|
CN105669864B
(zh)
|
2015-12-23 |
2018-10-16 |
杭州尚健生物技术有限公司 |
抗人程序性死亡受体1抗体及其制备方法和用途
|
EP3402520A4
(en)
|
2016-01-14 |
2019-01-02 |
BPS Bioscience, Inc. |
Anti-pd-1 antibodies and uses thereof
|
US10294299B2
(en)
|
2016-01-22 |
2019-05-21 |
MabQuest SA |
Immunological reagents
|
WO2017132827A1
(en)
|
2016-02-02 |
2017-08-10 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
CN107286242B
(zh)
|
2016-04-01 |
2019-03-22 |
中山康方生物医药有限公司 |
抗pd-1的单克隆抗体
|
DK3458478T3
(da)
|
2016-05-18 |
2021-03-22 |
Boehringer Ingelheim Int |
Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
|
CN106008714B
(zh)
|
2016-05-24 |
2019-03-15 |
瑞阳(苏州)生物科技有限公司 |
抗人pd-1人源化单克隆抗体及其应用
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
WO2018026248A1
(ko)
|
2016-08-05 |
2018-02-08 |
주식회사 와이바이오로직스 |
프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도
|
JP6960635B2
(ja)
|
2016-08-15 |
2021-11-05 |
国立大学法人北海道大学 |
抗pd−1抗体
|
CN106977602B
(zh)
|
2016-08-23 |
2018-09-25 |
中山康方生物医药有限公司 |
一种抗pd1单克隆抗体、其药物组合物及其用途
|
MX2019002946A
(es)
|
2016-09-14 |
2019-09-26 |
Abbvie Biotherapeutics Inc |
Anticuerpos anti-pd-1 y sus usos.
|
RU2752832C2
(ru)
|
2016-09-16 |
2021-08-09 |
Шанхай Хенлиус Байотек, Инк. |
Анти-pd-1 антитела
|
KR20190065183A
(ko)
|
2016-10-15 |
2019-06-11 |
이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 |
Pd-1 항체
|
AU2017354070A1
(en)
|
2016-11-01 |
2019-05-16 |
Anaptysbio, Inc. |
Antibodies directed against programmed death- 1 (PD-1)
|
MA46708B1
(fr)
|
2016-11-02 |
2021-10-29 |
Jounce Therapeutics Inc |
Anticorps anti-pd1 et leurs utilisations
|
WO2018087143A2
(en)
|
2016-11-08 |
2018-05-17 |
Actigen Ltd |
Anti-pd-1 antibodies
|
JP7178999B2
(ja)
|
2016-11-18 |
2022-11-28 |
シムフォゲン・アクティーゼルスカブ |
抗pd-1抗体および組成物
|
CN106519034B
(zh)
|
2016-12-22 |
2020-09-18 |
鲁南制药集团股份有限公司 |
抗pd-1抗体及其用途
|
WO2018119474A2
(en)
|
2016-12-23 |
2018-06-28 |
Remd Biotherapeutics, Inc. |
Immunotherapy using antibodies that bind programmed death 1 (pd-1)
|
EP3589652A4
(en)
|
2017-03-04 |
2021-05-05 |
Xiangtan Tenghua Bioscience |
RECOMBINANT ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH 1 (PD-1) AND THEIR USES
|
CN106939049B
(zh)
|
2017-04-20 |
2019-10-01 |
苏州思坦维生物技术股份有限公司 |
拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
|
MX2019013751A
(es)
|
2017-05-16 |
2020-01-15 |
Jiangsu Hengrui Medicine Co |
Composicion farmaceutica de anticuerpos del ligando 1 de muerte programada y su uso.
|
WO2018217227A1
(en)
|
2017-05-24 |
2018-11-29 |
Immunomedics, Inc. |
Novel anti-pd-1 checkpoint inhibitor antibodies that block binding of pd-l1 to pd-1
|
AU2018282094A1
(en)
|
2017-06-05 |
2019-12-12 |
Janssen Biotech, Inc. |
Antibodies that specifically bind PD-1 and methods of use
|
WO2019005635A2
(en)
|
2017-06-25 |
2019-01-03 |
Systimmune, Inc. |
ANTI-PD-1 ANTIBODIES AND METHODS OF PREPARATION AND USE
|
CN111133005A
(zh)
|
2017-09-07 |
2020-05-08 |
奥古斯塔大学研究所公司 |
程序性细胞死亡蛋白1抗体
|